Xilio Development Stock Performance
| XLO Stock | USD 0.79 0.01 1.25% |
The firm maintains a market beta of 1.28, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Xilio Development will likely underperform. At this point, Xilio Development has a negative expected return of -0.26%. Please make sure to check out Xilio Development's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Xilio Development performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Xilio Development has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in November 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Disposition of 37296 shares by Christopher Frankenfield of Xilio Development at 16.0 subject to Rule 16b-3 | 07/30/2024 |
2 | Acquisition by Christopher Frankenfield of 52000 shares of Xilio Development at 0.895 subject to Rule 16b-3 | 08/02/2024 |
3 | Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results | 08/08/2024 |
4 | Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference | 08/28/2024 |
5 | Acquisition by Russo Rene of 474000 shares of Xilio Development at 1.08 subject to Rule 16b-3 | 09/10/2024 |
6 | Disposition of 7186489 shares by Flynn James E of Xilio Development subject to Rule 16b-3 | 09/27/2024 |
7 | Acquisition by Kevin Brennan of 26000 shares of Xilio Development at 0.75 subject to Rule 16b-3 | 10/01/2024 |
8 | Xilio Therapeutics Announces Inducement Grants UnderNasdaq Listing Rule 5635 | 10/02/2024 |
9 | Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer th Annual Meeting | 10/04/2024 |
| Begin Period Cash Flow | 121.9 K |
Xilio |
Xilio Development Relative Risk vs. Return Landscape
If you would invest 99.00 in Xilio Development on July 20, 2024 and sell it today you would lose (20.00) from holding Xilio Development or give up 20.2% of portfolio value over 90 days. Xilio Development is generating negative expected returns assuming volatility of 4.3918% on return distribution over 90 days investment horizon. In other words, 39% of stocks are less volatile than Xilio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Xilio Development Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xilio Development's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xilio Development, and traders can use it to determine the average amount a Xilio Development's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0582
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XLO |
Estimated Market Risk
| 4.39 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Xilio Development is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xilio Development by adding Xilio Development to a well-diversified portfolio.
Xilio Development Fundamentals Growth
Xilio Stock prices reflect investors' perceptions of the future prospects and financial health of Xilio Development, and Xilio Development fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xilio Stock performance.
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (6.23) % | ||||
| Current Valuation | (31.11 M) | ||||
| Shares Outstanding | 43.95 M | ||||
| Price To Book | 1.05 X | ||||
| Price To Sales | 14.73 X | ||||
| Gross Profit | (56.77 M) | ||||
| EBITDA | (77.23 M) | ||||
| Net Income | (76.4 K) | ||||
| Cash And Equivalents | 159.41 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 11.46 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 9.17 X | ||||
| Book Value Per Share | 0.76 X | ||||
| Cash Flow From Operations | (68.62 K) | ||||
| Earnings Per Share | (1.98) X | ||||
| Market Capitalization | 34.72 M | ||||
| Total Asset | 60.93 M | ||||
| Retained Earnings | (325.51 M) | ||||
| Working Capital | 103.38 M | ||||
About Xilio Development Performance
By examining Xilio Development's fundamental ratios, stakeholders can obtain critical insights into Xilio Development's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Xilio Development is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.25) | (1.32) | |
| Return On Capital Employed | (1.76) | (1.85) | |
| Return On Assets | (1.25) | (1.32) | |
| Return On Equity | (2.07) | (1.97) |
Things to note about Xilio Development performance evaluation
Checking the ongoing alerts about Xilio Development for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xilio Development help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xilio Development generated a negative expected return over the last 90 days | |
| Xilio Development has some characteristics of a very speculative penny stock | |
| Xilio Development has high historical volatility and very poor performance | |
| Xilio Development has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (76.4 K) with loss before taxes, overhead, and interest of (56.77 M). | |
| Xilio Development has about 159.41 M in cash with (68.62 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Xilio Development has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer th Annual Meeting |
- Analyzing Xilio Development's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xilio Development's stock is overvalued or undervalued compared to its peers.
- Examining Xilio Development's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xilio Development's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xilio Development's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xilio Development's stock. These opinions can provide insight into Xilio Development's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xilio Development. If investors know Xilio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xilio Development listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Revenue Per Share 0.054 | Return On Assets (0.46) | Return On Equity (1.30) |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xilio Development's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.